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Rationale of Novel Interventions for Resistant
HypertensionFigure 1 Extravascular device (Starfix) placed on a leftHypertension treatment is challenging. As effective thera-
peutic measures were lacking, severe hypertension in the
first half of the 20th century was successfully treated by
performing an open surgical thoracolumbar sympathec-
tomy.1 With the advent of medical therapy, such extensive
operative procedures lost popularity, particularly because
of severe adverse events. However, despite current optimal
pharmacological treatment including the combination of
three anti-hypertensive medications of which one is
a diuretic, blood pressure control remains disappointingly
unsatisfactory in many patients.2 As resistant hypertension
is accompanied by severe cardiovascular morbidity and
mortality, it is crucial to re-explore non-pharmacological
blood pressure-lowering strategies. The past few years
have witnessed the development of novel minimally inva-
sive interventions modulating various levels of the auto-
nomic nervous system. The present article aims to discuss
some relevant developments of non-pharmacological anti-
hypertensive treatment modalities.
Renal Sympathetic Denervation
In 2009, a 59-year-old male was successfully treated for
resistant hypertension by renal sympathetic nerve ablation.
During this intervention, a catheter is advanced into the
renal arteries and four to six discrete low-power radio
frequency treatments are applied along the length of both
renal arteries.3 The rationale for this treatment is the
denervation of sympathetic efferent nerve fibres respon-
sible for increasing blood pressure by renal vasoconstric-
tion, enhanced sodium/water reabsorption and renin
secretion. The denervation of renal afferents results in
reduced central sympathetic outflow and lower blood
pressure. The efficacy of this new technique was confirmed
in the Symplicity HTN-2 trial including 106 patients,
randomly allocated to renal denervation or control groups.
After 6 months, office-based blood pressure measurements
in the renal denervation group reduced by 32/12 mm Hg (SD
23/11, baseline of 178/96 mm Hg, p < 0.0001), whereas1078-5884/$36 ª 2011 European Society for Vascular Surgery. Publishe
doi:10.1016/j.ejvs.2011.07.014they did not differ from baseline in the control group
(change of 1/0 mm Hg (21/10), baseline of 178/97 mm Hg,
p Z 0.77 systolic and p Z 0.83 diastolic). Twenty-four h
ambulatory blood pressure (evaluated in only half of the
patients) decreased by 11/7 mm Hg in the renal denerva-
tion group (SD 15/11, p Z 0.006 systolic and p Z 0.014
diastolic), whereas there was no change in the control
group. This discrepancy in blood pressure reduction may be
caused by the ‘white coat effect’, which can lead to an
overestimation of the blood-lowering effect, when office-
based blood pressure is measured. It may therefore seem
more appropriate to use ambulatory blood pressure for
determining the treatment effect.4 The investigators tried
to address the question of possible reinnervation of renal
nerves by reporting the durability of denervation after 2
years. Although it is unclear why only 18 patients reached
the 24-month end point, clinical evidence of reinnervationcarotid sinus of a human cadaver.
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Figure 2 Schematic drawing showing the working mechanism of mechanical carotid baroreceptor stimulation. Strain in the
arterial wall of the carotid sinus is increased by changing its geometrical shape by A) an extravascular device or B) an intravascular
device.
558 Editorialwas not observed. Renal denervation appeared safe as
cholesterol embolic events, de novo renal artery stenosis or
renal artery aneurysm were not reported. A limitation of
this technique is an unsuitable renal artery anatomy
precluding catheterisation in almost 20% of patients.5
Electrical Carotid Baroreceptor Stimulation
The first successful experience of human blood pressure
reduction by continuous electrical stimulation of the
carotid baroreceptors was reported in 2004.6 During this
procedure, carotid arteries are surgically exposed and
electrodes are placed around the carotid sinuses. Electrode
leads are connected to a subcutaneously implanted pulse
generator responsible for continuous electrical baroreflex
stimulation. In hypertensive patients, the baroreceptor
reflex is thought to have adjusted to a higher operating
pressure by a shift in pressure threshold.7 Electrical stim-
ulation may lower the baroreceptor set point with conse-
quent lowered blood pressures due to a reduced central
sympathetic outflow. Data from the DEBUT trial using the
Rheos implantable carotid stimulator (CRVx, Minneapolis,
MN, USA) suggest a substantial reduction of blood pressure
over 3 years after device implantation. A large randomised
controlled study (nZ 265) investigating efficacy and safety
of electrical carotid baroreceptor stimulation is currently
being conducted. For obvious reasons, patients with
a carotid stenosis >50% are excluded from treatment.8 A
clear disadvantage of this procedure is its invasiveness with
possible adverse events, such as infection, cranial nerve
injury or long-term arterial complications. However, no de
novo carotid artery stenosis was documented after 1 year of
follow-up.9
Future Concepts in Blood Pressure Control
Triggered by the physiological blood-lowering effect of
carotid sinus massage, a simple passive extravascular
device positioned around the carotid sinus (Starfix, Vascular
Dynamics, Israel) has been developed (Fig. 1). This device
continuously increases mechanical strain at the carotidsinus by changing the geometric shape of the arterial wall
while preserving arterial pulsatility (Fig. 2). Augmentation
of baroreceptor firing and, as in electrical baroreceptor
stimulation, inhibition of central sympathetic outflow
causes subsequent blood pressure reduction. In view of
minimally invasive endovascular procedures, an intravas-
cular stent-like nitinol device (Mobius, Vascular Dynamics,
Israel) has been developed, which meets the requirements
to reduce blood pressure by means of mechanical carotid
baroreceptor stimulation. Proof-of-concept and safety
studies are underway for both devices.
Resistant hypertension treatment may be boosted by
the recent advent of these exciting new invasive and
minimally invasive procedures modulating the autonomic
nervous system. These novel interventions may prove
a valuable adjunct to medication in lowering blood
pressure and may result in a substantial reduction of life-
long anti-hypertensive drugs. As carotid baroreceptor
stimulation and renal sympathetic denervation act on
different levels of the autonomic nervous system,
a combination of these approaches may hypothetically
act synergistically. However, long-term studies with
sufficient power are required to evaluate efficacy, dura-
bility and safety of these interventional techniques in the
treatment of resistant hypertension and its cardiovas-
cular adverse sequels.
Conflict of Interest/Funding
None.
References
1 Grimson KS, Organ ES, Anderson B. Results of treatment of
patients with hypertension by total thoracic and partial to total
lumbar sympathectomy, splanchnicectomy and celiac ganglio-
nectomy. Ann Surg 1949;129:850e71.
2 Kaplan NM. Resistant hypertension. J Hypertens 2005;23:
1441e4.
3 Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal
sympathetic-nerve ablation for uncontrolled hypertension. NEJM
2009;361(9):932e4.
Editorial 5594 Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE,
Bohm M. Renal sympathetic denervation in patients with
treatment-resistant hypertension (The symplicity HTN-2
trial): a randomised controlled trial. Lancet 2010;376(9756):
1903e9.
5 SymplicityHTN-1 Investigators. Catheter-based renal sympathetic
denervation for resistant hypertension: durability of blood pres-
sure reduction out to 24months.Hypertension 2011;57(5):911e7.
6 Mohaupt MS, Cain C, Fey FJ. Chronic electrical activation of the
carotid sinus baroreflex by implanted electrodes for blood
pressure reduction in man: first experience in a hypertensive
patient. Kidney Blood Press Res 2004;27:299.
7 Kougias P, Weakley SM, Yao Q, Lin PH, Chen C. Arterial barore-
ceptors in the management of systemic hypertension. Med Sci
Monit 2010;16(1):1e8.
8 Bisognano J, Sica D, Nadim M, Sanchez L, Bakris G. Results from
the Rheos pivotal trial. Baroreflex activation therapy sustainably
lowers blood pressure in patients with resistant hypertension.
Presented at: Annual Scientific Session of the American College
of Cardiology, April 2011, New Orleans, US.
9 Scheffers IJ, Kroon AA, Schmidli J, Jordan J, Tordoir JH,
Mohaupt MG. Novel carotid baroreflex activation therapy in
resistant hypertension: results of a European multi-center
feasibility and proof-of principle study. J Am Coll Cardiol 2010;
56(15):1254e8.R.J. Toorop*
Department of Vascular Surgery, University Medical
Center, PO box 85500, 3508 GA Utrecht,
The Netherlands
M.R. Scheltinga
Department of Surgery, Ma´xima Medical Center,
Veldhoven, The Netherlands
J.-B. Ricco
Department of Vascular Surgery,
University Hospital, Poitiers, France
F.L. Moll
Department of Vascular Surgery, University Medical
Center, PO box 85500, 3508 GA Utrecht,
The Netherlands
*Corresponding author. Tel.: þ31 887556965;
fax: þ31 887509111.
E-mail address: r.j.toorop@umcutrecht.nl (R.J. Toorop)
Available online 24 August 2011
